INSM - Insmed Inc logo

Insmed Inc

INSM
Rev 1147xtop 1%20Y
Compare INSM Hold

Insmed Inc develops and commercializes therapies for serious and rare diseases, focusing on treatments for lung infections, bronchiectasis, and muscular dystrophy. Its product pipeline includes ARIKAYCE and novel gene therapies in various clinical trial phases.

โš•๏ธ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 30 years ago โ†’$45,124today

Score Overview

1 Year
Score
Net Growth31.44%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth87.60%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score4.0
Net Growth-101.38%
Net Trend20%
Net Income Consistencyโ€”
Rev Growth6x
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth-396.57%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend90%
Revenue Consistency
20 Years
Score2.8
Net Growth-13x
Net Trend30%
Net Income Consistency
Rev Growth1147x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-8x
Net Trend35%
Net Income Consistency
Rev Growth18960x
Rev Trend58%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Insmed Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • INSM

2011: 65.0% ยท 2021: 98.8% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-29
$ 115.63โ€”
1 Year2025-09-29
$ 141.65-18.37%
5 Years2021-09-29
$ 26.23340.83%
10 Years2016-09-29
$ 13.948x
20 Years2006-09-29
$ 13.608x
30 Years1996-09-27
$ 2.5645x
All Time2000-06-01
$ 165.00-29.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1.13B-$ 875M$ 1.16B
2025$ 606M-$ 1.27B$ 1.43B
2024$ 363M-$ 913M$ 1.43B
2023$ 305M-$ 749M$ 780M
2022$ 245M-$ 481M$ 1.14B
2021$ 188M-$ 434M$ 716M
2020$ 164M-$ 294M$ 532M
2019$ 136M-$ 254M$ 487M
2018$ 9M-$ 324M$ 495M
2017$ 0.00-$ 192M$ 381M
2016$ 0.00-$ 176M$ 162M
2015$ 0.00-$ 118M$ 282M
2014$ 11M-$ 79M$ 159M
2013$ 11M-$ 56M$ 113M
2012$ 0.00-$ 41M$ 92M
2011$ 4M-$ 59M$ 76M
2010$ 6M-$ 6M$ 108M
2009$ 10M$ 118M$ 122M
2008$ 11M-$ 15M$ 2M
2007$ 7M-$ 19M$ 16M
2006$ 991K-$ 56M$ 24M
2005$ 131K-$ 40M$ 18M
2004$ 137K-$ 27M$ 9M
2003$ 150K-$ 10M$ 29M
2002$ 1M-$ 36M$ 27M
2001$ 296K-$ 37M$ 51M
IPO2000$ 60K-$ 79M$ 83M
INSM - Insmed Inc logo

Insmed Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 164M to $ 606M and net income went from -$ 294M to -$ 1.27B. Revenue increased in every one of those 5 years; net income in 1.

Across Insmed Inc's full reported history, from 2000 to 2025, revenue grew from $ 60K to $ 606M and net income went from -$ 79M to -$ 1.27B. Revenue increased in 58% of the years measured; net income in 35%.

Insmed Inc currently holds a 20-year HDB Score of 2.8 out of 10. How the HDB Score is calculated.

Membership

Continue INSMโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,814 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies